Kindstar Globalgene Technology (HKSE:09960) Tax Provision : HK$-9 Mil (TTM As of Jun. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Kindstar Globalgene Technology Tax Provision?

Kindstar Globalgene Technology's tax provision for the six months ended in Jun. 2024 was HK$-5 Mil. Its tax provision for the trailing twelve months (TTM) ended in Jun. 2024 was HK$-9 Mil.

Kindstar Globalgene Technology Tax Provision Historical Data

The historical data trend for Kindstar Globalgene Technology's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kindstar Globalgene Technology Tax Provision Chart

Kindstar Globalgene Technology Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Tax Provision

Get a 7-Day Free Trial

-1.09

-9.21

-0.30

-6.51

-7.52

Kindstar Globalgene Technology Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Tax Provision	Get a 7-Day Free Trial						-11.14	4.10	-3.51	-4.01	-4.89

Kindstar Globalgene Technology Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-9 Mil.

Kindstar Globalgene Technology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Kindstar Globalgene Technology Inc (HKSE:09960) » Definitions » Tax Provision

Comparable Companies

Traded in Other Exchanges

N/A

Address

Biolake D2-1, 666 Gaoxin Road, East Lake High Tech Zone, Hubei Province, Wuhan, CHN

Website

https://www.kindstar.com.cn

Kindstar Globalgene Technology Inc is principally engaged in the provision of clinical testing services in China. It organizes the business into the following segments; hematology testing, genetic disease and rare disease testing, infectious disease testing, oncology testing, neurology testing, maternity-related testing, COVID-19-related testing, routine testing, scientific research services and CRO, and other segments provide testing services for R&D projects and others and miscellaneous services.

Executives

Cpechina Fund Iii, L.p.	2201 Interest of corporation controlled by you
Ck Lab Tech Investment Limited	2101 Beneficial owner
Cpe Funds Iii Limited	2201 Interest of corporation controlled by you
Cpe Holdings International Limited	2201 Interest of corporation controlled by you
Cpe Holdings Limited	2201 Interest of corporation controlled by you
Huang Shiang	2101 Beneficial owner
Tu Zanbing
Huang Zuie-chin	2101 Beneficial owner
Ningbo Meishan Bonded Port Zone Ruifu Bojian Investment Management Co., Ltd.
Jackson Hole Trust Company
Huang Bo
Kernelstar Limited	2301 Trustee
Kastle Limited	2301 Trustee
Guo Gui-rong	2202 Interest of your spouse
Morningside Holdings (asia) Limited	2201 Interest of corporation controlled by you

Kindstar Globalgene Technology Headlines

No Headlines